Blocklisting Interim Review

RNS Number : 1338I
Hutchison China Meditech Limited
01 July 2013
 



 

 

 

Hutchison China MediTech Limited ("Chi-Med")

(AIM: HCM)

 

Blocklisting Six Monthly Return

 

 

London: Monday, 1 July 2013: Chi-Med announces the following blocklisting six monthly return:

 

1.

Name of applicant:

 


Hutchison China MediTech Limited

2.

Name of scheme:

 


Hutchison China MediTech Limited Share Option Scheme

 

3.

Period of return:                                 

 


From 29 December 2012 to 28 June 2013

 

4.

Balance under scheme from previous return:

 


1,724,279 ordinary shares of US$1 each

 

5.

The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:

 


Nil

6.

Number of securities issued/allotted under scheme during period:


3,000 ordinary shares of US$1 each





7.

Balance under scheme not yet issued/allotted at end of the period:

 


1,721,279 ordinary shares of US$1 each

8.

Number and class of securities originally listed and the date of admission:

 


2,560,606 ordinary shares of US$1 each admitted on 26 June 2007

9.

Total number of securities in issue at the end of the period:


52,051,448 ordinary shares of US$1 each





Name of contact:

 


Christian Hogg

Address of contact:

 


21/F., Hutchison House, 10 Harcourt Road, Hong Kong

 

Telephone number of contact:

 


+852 2121 8200

 

 

 

Ends

 

 

 

 

 

Enquiries

 

Chi-Med

Christian Hogg, CEO

Telephone:      +852 2121 8200



Panmure Gordon (UK) Limited

Richard Gray

Andrew Potts

Grishma Patel

Telephone:      +44 20 7886 2500

 



Citigate Dewe Rogerson

Anthony Carlisle

David Dible

Telephone:      +44 20 7638 9571

Mobile:             +44 7973 611 888

Mobile:             +44 7967 566 919

 

 

About Chi-Med

 

Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006.  It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

 

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRKMGZVLRVGFZG
UK 100

Latest directors dealings